Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NKTX

Nkarta Inc

Feb 13 • 04:00PM ET

1.97

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA FATE BMRN BLUE EDIT ALLO SGMO CLLS BLRX

| Held by: VTI IWM VXF IWN VTWO PRFZ IWC AVSC DFAS VTWV

Index	RUT	P/E	-	EPS (ttm)	-1.39	Insider Own	20.11%	Shs Outstand	71.02M	Perf Week	-2.48%
Market Cap	139.93M	Forward P/E	-	EPS next Y	-1.23	Insider Trans	-0.22%	Shs Float	56.74M	Perf Month	-4.83%
Enterprise Value	-65.77M	PEG	-	EPS next Q	-0.31	Inst Own	74.54%	Short Float	11.52%	Perf Quarter	0.51%
Income	-102.61M	P/S	-	EPS this Y	17.90%	Inst Trans	-0.26%	Short Ratio	8.82	Perf Half Y	-10.45%
Sales	0.00M	P/B	0.41	EPS next Y	5.99%	ROA	-21.39%	Short Interest	6.54M	Perf YTD	6.49%
Book/sh	4.76	P/C	0.50	EPS next 5Y	6.74%	ROE	-26.69%	52W High	2.74 -28.10%	Perf Year	-7.08%
Cash/sh	3.97	P/FCF	-	EPS past 3/5Y	15.10% -19.86%	ROIC	-25.14%	52W Low	1.31 50.38%	Perf 3Y	-61.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.29% 6.43%	Perf 5Y	-96.31%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	25.84%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.23	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.82	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	15.23	EPS Q/Q	23.85%	SMA20	-9.65%	Beta	0.54	Target Price	11.80
Payout	-	Debt/Eq	0.23	Sales Q/Q	-	SMA50	-1.86%	Rel Volume	0.58	Prev Close	1.97
Employees	157	LT Debt/Eq	0.21	Earnings	Nov 10 AMC	SMA200	-1.61%	Avg Volume	741.32K	Price	1.97
IPO	Jul 10, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.89% -	Trades		Volume	432,176	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$14
Aug-14-24	Upgrade	Raymond James	Outperform → Strong Buy	$16
Mar-22-24	Downgrade	Raymond James	Strong Buy → Outperform	$13 → $16
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Oct-10-22	Initiated	Canaccord Genuity	Buy	$25
Jul-28-22	Initiated	Needham	Buy	$26
Jul-18-22	Initiated	SVB Leerink	Outperform	$30
Mar-11-22	Initiated	Raymond James	Outperform	$17
Mar-08-22	Initiated	H.C. Wainwright	Buy	$25
Jan-06-22	Initiated	William Blair	Outperform
Nov-18-21	Initiated	SMBC Nikko	Outperform	$50
Jul-16-21	Initiated	Oppenheimer	Outperform	$75
Aug-04-20	Initiated	Stifel	Buy	$41
Aug-04-20	Initiated	Mizuho	Buy	$34
Aug-04-20	Initiated	Evercore ISI	Outperform	$55
Aug-04-20	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-02-25 07:09AM	Nkarta to Participate in Evercore Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-30-25 01:14PM	Nkarta to Participate in November Investor Conferences (GlobeNewswire)
Oct-22-25 10:07AM	Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting (GlobeNewswire) -7.95%
Sep-02-25 08:01AM	Nkarta to Participate in a September Investor Conference (GlobeNewswire)
04:01PM	Loading…
Aug-12-25 04:01PM	Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +12.76%
Jul-23-25 08:01AM	Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +7.21%
Jun-06-25 08:52AM	Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus (GlobeNewswire)
May-19-25 12:00PM	Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
May-15-25 03:46PM	Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space (Benzinga) -8.02%
May-14-25 04:01PM	Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-14-25 12:00PM	Nkarta (NKTX) Upgraded to Buy: Here's Why (Zacks) +7.94%
Apr-01-25 08:01AM	Nkarta to Participate in an April Investor Conference (GlobeNewswire)
Mar-31-25 10:41AM	Nkarta: Grinding Lower, Trying To Find Support (Seeking Alpha) -8.00%
10:15AM	Nkarta: Betting On The Turnaround (Seeking Alpha)
06:55AM	Loading…
Mar-27-25 06:55AM	Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy (BioPharma Dive) +43.80%
Mar-26-25 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-20-25 09:35AM	Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-19-25 09:35AM	Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-25-25 08:01AM	Nkarta to Participate in March Investor Conferences (GlobeNewswire)
Dec-05-24 06:01AM	Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 (GlobeNewswire)
Nov-26-24 07:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire)
Nov-22-24 06:50AM	Nkarta price target lowered to $16 from $20 at Mizuho (TipRanks)
Nov-12-24 08:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire) -10.03%
Nov-07-24 04:02PM	Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-09-24 08:00AM	Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month (Benzinga)
Sep-03-24 04:01PM	Nkarta to Participate in Upcoming Investor Conference (GlobeNewswire)
Aug-14-24 12:37PM	Why Nkarta Stock Is Soaring Today (Motley Fool)
Aug-13-24 09:03PM	Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
06:00AM	Loading…
Jul-24-24 06:00AM	Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus (GlobeNewswire)
Jul-16-24 06:01AM	Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President (GlobeNewswire) +13.96%
Jul-10-24 12:00PM	Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know (Zacks)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-27-24 06:00AM	Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications (GlobeNewswire)
Jun-13-24 04:01PM	Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors (GlobeNewswire)
May-10-24 02:56PM	Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis (GuruFocus.com)
May-09-24 10:57PM	NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-07-24 06:30AM	Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar (InvestorPlace)
Apr-03-24 04:02PM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-24 04:06PM	Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday (Investor's Business Daily) +17.60% -5.91%
06:30AM	Nkarta Announces Pricing of $240 Million Underwritten Offering (GlobeNewswire)
Mar-23-24 05:31AM	Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment (GuruFocus.com)
Mar-22-24 04:03PM	Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line (Investor's Business Daily) -31.28% +17.60%
09:18AM	Nkarta's blood cancer CAR stalls again, with falling response rate forcing it out of the race (FierceBiotech.com)
Mar-21-24 10:54PM	NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-19-24 07:29AM	3 Overlooked Stocks Ready to Capture the Market by Storm (InvestorPlace) +7.19%
Feb-29-24 06:30AM	3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket (InvestorPlace) +11.13%
Feb-28-24 08:01AM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:19PM	Last Call! 7 Small-Cap Stocks Ready to Explode in Value (InvestorPlace) -7.66%
Feb-08-24 09:32AM	3 Under-the-Radar Stocks Set to Soar 300% by 2026 (InvestorPlace) +7.87%
Feb-06-24 12:50PM	3 Sleeper Stocks With Serious Potential to Make You a Millionaire (InvestorPlace) +11.95%
Feb-05-24 12:41PM	3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential (InvestorPlace) -5.59%
Feb-04-24 08:00AM	Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge (InvestorPlace)
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire)
Dec-09-23 08:31PM	Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition (GlobeNewswire)
Dec-08-23 12:00PM	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy (Zacks)
Nov-14-23 03:56PM	T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta Inc (GuruFocus.com) +20.42%
Nov-09-23 04:02PM	Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga)
Nov-07-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 02:06PM	Want To Invest In Penny Stocks? Here Are Three That Analysts Think Could Deliver Over 300% Returns (Benzinga)
Oct-18-23 10:47AM	Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug (Zacks)
01:18AM	'The world increasingly needs Arm,' says KeyBanc: 4 big analyst picks (Investing.com)
Oct-17-23 08:17PM	Nkarta stock soars 112% after FDA clears cell therapy to go beyond cancer into lupus (FierceBiotech.com) +112.16%
11:47AM	Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis (PR Newswire)
07:01AM	Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis (GlobeNewswire)
Oct-16-23 04:01PM	Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures (GlobeNewswire)
Oct-02-23 03:07PM	3 Promising Biotech Stocks That Will Make Early Investors Rich (InvestorPlace) -5.76%
Aug-10-23 07:01AM	Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-03-23 08:02AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire)
Jul-31-23 06:30PM	3 Hidden Penny Stocks That Could Turn $100 into $10,000 (InvestorPlace) +6.51%
Jul-05-23 04:02PM	Nkarta Appoints Alyssa Levin Chief Financial and Business Officer (GlobeNewswire) -6.87%
Jun-28-23 09:35AM	Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks (Zacks) -11.74%
Jun-27-23 01:02PM	Why Shares of Nkarta Are Slumping Tuesday (Motley Fool) -37.97%
07:01AM	Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Jun-26-23 04:01PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +12.24%
Jun-10-23 10:47AM	Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-11-23 04:02PM	Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-09-23 07:15AM	We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely (Simply Wall St.)
May-07-23 12:50PM	7 Stocks With Promising Upside Potential for 100% Returns (InvestorPlace)
Apr-17-23 05:01PM	Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 09:06PM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire) +14.06%
Apr-11-23 09:46AM	3 Biotech Stocks to Watch for Potential Breakthroughs (InvestorPlace)
Mar-30-23 04:01PM	Nkarta Announces Departure of Chief Financial & Business Officer (GlobeNewswire)
Mar-16-23 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-17-23 05:35AM	Nkarta, Inc. (NASDAQ:NKTX) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Feb-09-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-23 04:30PM	Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer (GlobeNewswire) -7.77%
Dec-05-22 07:02AM	Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (GlobeNewswire) -5.12%
Dec-02-22 04:02PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program (GlobeNewswire)
Nov-09-22 04:02PM	Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -6.24%
Nov-07-22 08:52AM	Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting (GlobeNewswire)
Nov-02-22 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-24-22 09:34AM	Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-23-22 07:30AM	7 Unknown Biotech Stocks That Could Rocket in 2023 (InvestorPlace)

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HASTINGS PAUL J	Chief Executive Officer	Jan 15 '26	Sale	2.07	26,046	53,915	390,023	Jan 20 05:39 PM
Mahmood Nadir	President	Jan 15 '26	Sale	2.07	5,649	11,693	167,727	Jan 20 05:38 PM
HASTINGS PAUL J	Chief Executive Officer	Jun 18 '25	Sale	1.79	1,790	3,204	320,069	Jun 20 04:08 PM

Open in Screener

DSGN

Design Therapeutics Inc

Feb 13 • 04:00PM ET

10.07

+0.02 0.20 %

Healthcare • Biotechnology • USA • NASD

DSGN Design Therapeutics Inc daily Stock Chart

Peers: PFE REGN VRTX MRNA BNTX CRSP EDIT NTLA SGMO BEAM

| Held by: VTI IWM VXF IBB IWN DWAS SCHA FESM VTWO IWC

Index	RUT	P/E	-	EPS (ttm)	-1.19	Insider Own	45.10%	Shs Outstand	56.96M	Perf Week	-1.95%
Market Cap	573.63M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	0.00%	Shs Float	31.27M	Perf Month	2.76%
Enterprise Value	369.40M	PEG	-	EPS next Q	-0.35	Inst Own	43.84%	Short Float	6.38%	Perf Quarter	32.33%
Income	-67.45M	P/S	-	EPS this Y	-47.95%	Inst Trans	-4.36%	Short Ratio	5.43	Perf Half Y	95.16%
Sales	0.00M	P/B	2.87	EPS next Y	0.46%	ROA	-28.49%	Short Interest	1.99M	Perf YTD	7.36%
Book/sh	3.51	P/C	2.79	EPS next 5Y	-18.76%	ROE	-29.83%	52W High	10.97 -8.20%	Perf Year	153.65%
Cash/sh	3.62	P/FCF	-	EPS past 3/5Y	-10.99% -88.52%	ROIC	-33.62%	52W Low	2.60 287.31%	Perf 3Y	45.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.87% 6.86%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-40.26%	Oper. Margin	-	ATR (14)	0.63	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	18.71	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.41	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	18.71	EPS Q/Q	-29.57%	SMA20	-0.85%	Beta	1.64	Target Price	14.40
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	3.43%	Rel Volume	0.42	Prev Close	10.05
Employees	54	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	SMA200	57.46%	Avg Volume	367.34K	Price	10.07
IPO	Mar 26, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.61% -	Trades		Volume	154,083	Change	0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Oppenheimer	Outperform	$18
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform	$14
Dec-03-25	Initiated	Craig Hallum	Buy	$15
Nov-20-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$13
May-07-24	Upgrade	Piper Sandler	Neutral → Overweight	$6 → $12
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $6
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral	$19 → $6
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform	$6
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$23 → $7
May-04-23	Upgrade	Goldman	Sell → Neutral	$6
Jun-10-22	Initiated	Wedbush	Outperform	$21
May-02-22	Initiated	RBC Capital Mkts	Outperform	$30
Jan-19-22	Initiated	Goldman	Sell	$10
Apr-20-21	Initiated	SVB Leerink	Outperform	$36
Apr-20-21	Initiated	Piper Sandler	Overweight	$42
Apr-20-21	Initiated	Goldman	Neutral	$28

Show Previous Ratings

Nov-26-25 08:00AM	Design Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-20-25 09:21AM	Here Are Thursdays Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More (24/7 Wall St.) +7.22%
Nov-05-25 04:01PM	Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Sep-10-25 04:01PM	Design Therapeutics Appoints Justin Gover to Board of Directors (GlobeNewswire) -7.68%
Aug-27-25 08:00AM	Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Aug-07-25 04:01PM	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Second Quarter 2025 Financial Results (GlobeNewswire) -8.74% +7.81%
Jun-04-25 07:00AM	Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 (GlobeNewswire)
May-28-25 08:00AM	Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-25 08:00AM	Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference (GlobeNewswire)
May-07-25 04:01PM	Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results (GlobeNewswire) -8.26% +5.71%
May-02-25 07:58AM	Design Therapeutics reports positive outcomes from trial of DT-168 eye drops (Clinical Trials Arena)
May-01-25 08:00AM	Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy (GlobeNewswire)
Apr-21-25 04:01PM	Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 (GlobeNewswire) +10.31%
Apr-17-25 08:00AM	Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer (GlobeNewswire)
07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
12:00PM	Loading…
Mar-12-25 12:00PM	Design Therapeutics (DSGN) Upgraded to Buy: Here's Why (Zacks) -6.94%
Mar-10-25 07:07AM	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Design Therapeutics to Participate in Leerink's Global Healthcare Conference (GlobeNewswire) -7.00%
Nov-13-24 08:00AM	Design Therapeutics to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire) +8.54%
Nov-07-24 04:01PM	Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio (GlobeNewswire)
Sep-10-24 08:00AM	Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.69%
Aug-21-24 09:55AM	Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet (Zacks)
Aug-05-24 08:00AM	Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC Portfolio (GlobeNewswire)
May-22-24 08:50PM	The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains (InvestorPlace)
May-10-24 03:36PM	Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review (GuruFocus.com)
May-08-24 11:55PM	DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones (GlobeNewswire)
May-07-24 07:12AM	--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral (MT Newswires) +28.49%
06:30AM	Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Mar-20-24 10:31AM	Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.97%
06:58AM	Loading…
06:58AM	Q4 2023 Design Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:53PM	DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress (GuruFocus.com)
04:01PM	Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 06:30AM	Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update (GlobeNewswire)
Dec-18-23 12:00PM	Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update (GuruFocus.com) +11.71%
Nov-13-23 04:05PM	Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 (GlobeNewswire)
Aug-15-23 03:02PM	Why Shares of Design Therapeutics Are Plummeting on Tuesday (Motley Fool) -70.46%
09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly)
02:34AM	4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi (Investing.com)
Aug-14-23 04:05PM	Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
04:01PM	Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia (GlobeNewswire)
Jun-18-23 08:03AM	Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \ (Simply Wall St.)
May-31-23 06:30AM	Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) -6.01%
May-09-23 04:05PM	Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results (GlobeNewswire) -11.66%
May-08-23 06:05AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Apr-24-23 06:30AM	Design Therapeutics to Present Preclinical Data on its GeneTAC Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 (GlobeNewswire)
Apr-11-23 09:55AM	Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down (InvestorPlace)
Apr-04-23 02:47PM	Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound (TipRanks) -7.32%
Mar-14-23 04:05PM	Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Feb-08-23 06:30AM	Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire) -8.79%
Dec-21-22 06:46AM	Daily Vickers Top Buyers & Sellers for 12/21/2022 (Argus Research) +5.33%
Dec-14-22 05:15AM	Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN) (Simply Wall St.)
Dec-07-22 04:01PM	Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress (GlobeNewswire) -6.00% -33.33%
Nov-28-22 10:37AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-03-22 04:05PM	Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-17-22 04:05PM	Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022 (GlobeNewswire)
Sep-22-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Aug-08-22 04:05PM	Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 06:30AM	Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference (GlobeNewswire) +6.33%
Jun-21-22 09:57AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.) +6.24%
Jun-01-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-09-22 04:05PM	Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 06:30AM	Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC Molecule for the Treatment of Friedreich Ataxia (GlobeNewswire)
Mar-23-22 02:53PM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Mar-10-22 04:02PM	Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-09-22 06:30AM	Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022 (GlobeNewswire) +9.41%
Feb-28-22 04:05PM	Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC Molecule for Friedreich Ataxia (GlobeNewswire)
Feb-10-22 06:30AM	Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire) +7.02%
Feb-01-22 04:05PM	Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer (GlobeNewswire)
Jan-19-22 12:51PM	Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating (Benzinga) -5.86%
Dec-23-21 05:00AM	Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +5.09%
Nov-09-21 04:05PM	Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results (GlobeNewswire)
Sep-24-21 07:55AM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Sep-08-21 06:30AM	Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1 (GlobeNewswire)
Sep-03-21 07:33AM	4 Stocks Insiders Are Buying (Benzinga)
Aug-09-21 04:05PM	Design Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results (GlobeNewswire) +6.19%
Jun-26-21 04:30AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Jun-07-21 04:10PM	Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Design Therapeutics Expands Board of Directors with Key Appointments (GlobeNewswire)
May-10-21 04:05PM	Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results (GlobeNewswire) -6.82%
Mar-30-21 04:05PM	Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -13.20%
Mar-25-21 11:56PM	Design Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Logos Global Master Fund LP	Director	Nov 18 '25	Proposed Sale	7.43	120,000	891,600		Nov 18 04:28 PM
Logos Global Master Fund LP	Director	Nov 14 '25	Proposed Sale	7.06	620,000	4,377,200		Nov 14 04:18 PM
Logos Global Master Fund LP	Director	Nov 07 '25	Proposed Sale	6.87	415,000	2,851,050		Nov 07 05:24 PM
William Arsani	Director	Aug 13 '25	Sale	5.25	562,627	2,953,792	1,000,000	Aug 14 04:15 PM
Logos Opportunities Fund II LP	Director	Aug 13 '25	Proposed Sale	4.98	217,627	1,083,783		Aug 13 08:05 PM
Logos Global Master Fund LP	Director	Aug 13 '25	Proposed Sale	4.98	345,000	1,718,100		Aug 13 08:04 PM

NKTX

Nkarta Inc

DSGN

Design Therapeutics Inc

Upgrade your FINVIZ experience